Polar Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Polar Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-315,000	Closed	-$11.4M	–	268
2016 Q4	$11.4M	Buy	315,000 +25,000	+9%	+$998K	0.18%	145
2016 Q3	$13.3M	Buy	290,000 +72,433	+33%	+$3.78M	0.23%	127
2016 Q2	$10.9M	Sell	217,567 -645,000	-75%	-$34.3M	0.21%	131
2016 Q1	$46.2M	Buy	862,567 +125,967	+17%	+$7.39M	0.87%	36
2015 Q4	$48.3M	Buy	736,600 +521,600	+243%	+$32.2M	0.87%	35
2015 Q3	$12.1M	Buy	215,000 +24,000	+13%	+$1.56M	0.25%	126
2015 Q2	$11.3M	Sell	191,000 -329,000	-63%	-$20.3M	0.22%	136
2015 Q1	$32.4M	Sell	520,000 -230,000	-31%	-$13.4M	0.61%	52
2014 Q4	$43.1M	Buy	750,000 +389,787	+108%	+$21.7M	0.84%	33
2014 Q3	$19.4M	Sell	360,213 -64,787	-15%	-$3.43M	0.41%	79
2014 Q2	$22.3M	Buy	+425,000	New	+$21.7M	0.47%	70
2013 Q4	–	Sell	-100,000	Closed	-$3.78M	–	282
2013 Q3	$3.78M	Hold	100,000	–	–	0.1%	200
2013 Q2	$3.92M	Buy	+100,000	New	+$3.89M	0.14%	189

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Polar Capital's TEVA Position: Q1 2017 in Review

Polar Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 315,000 shares — an estimated $11.4M sold.

Polar Capital first reported a position in TEVA in Q2 2013 and held it in 13 quarters. The position peaked at $48.3M in Q4 2015. 688 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Polar Capital reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Polar Capital sold 315,000 Teva Pharmaceuticals shares in Q1 2017, an estimated $11.4M.
Polar Capital first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 13 quarters.
Polar Capital's Teva Pharmaceuticals position peaked at $48.3M in Q4 2015.
688 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Polar Capital's 13F filing for Q1 2017, filed 15 May 2017.